TARS · Tarsus Pharmaceuticals, Inc.
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| $606.33M | $451.36M | $182.95M | $17.45M | $25.82M | $57.03M | $0 | — | — | |
| $87.68M | $64.32M | $53.39M | $50.31M | $42.62M | $41.71M | $18.83M | $3.16M | — | |
| — | — | — | — | $44.95M | $25.4M | $8.17M | $1.14M | — | |
| $526.44M | $427.32M | $237.31M | $108.7M | $44.95M | — | — | — | — | |
| $961K | $961K | $540K | $133K | $0 | — | — | — | — | |
| — | — | — | $160.61M | $88.53M | $69.18M | $27M | $4.3M | — | |
| $654.87M | $522.33M | $303.52M | $160.61M | $88.53M | — | — | — | — | |
| -$48.54M | -$70.97M | -$120.57M | -$143.16M | -$62.71M | -$12.16M | -$27M | -$4.3M | — | |
| — | -15.72% | -65.9% | -820.53% | -242.92% | -21.32% | — | — | — | |
| $8.77M | $8.94M | $7.85M | $3.35M | $2.2M | $0 | — | — | — | |
| $9.19M | $6.61M | $5.02M | $7.27M | $617K | -$1.62M | $188K | -$371K | — | |
| — | -$64.36M | -$115.55M | -$135.89M | -$62.1M | -$13.77M | -$26.81M | — | — | |
| — | $2.06M | $0 | $0 | -$4000 | $55K | $1000 | $1000 | — | |
| -$46.48M | -$66.42M | -$115.55M | -$135.89M | -$62.09M | -$13.83M | -$26.81M | -$4.67M | -$1.32M | |
| — | -14.72% | -63.16% | -778.89% | -240.51% | -24.25% | — | — | — | |
| -$47.07M | -$66.22M | -$115.37M | -$135.82M | -$62.17M | -$13.83M | -$26.81M | -$4.67M | — | |
| USD/shares | — | -$1.59 | -$3.07 | -$4.62 | -$2.52 | -$0.67 | -$4.32 | — | — |
| USD/shares | — | -$1.59 | -$3.07 | -$4.62 | -$2.52 | -$0.67 | -$4.32 | — | — |
| shares | — | 41.78M | 37.6M | 29.38M | 24.62M | 20.55M | 6.21M | 2.36M | — |
| shares | — | 41.78M | 37.6M | 29.38M | 24.62M | 20.55M | 6.21M | 2.36M | — |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 236 similar-size Biotechnology companies (of 545 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $451,360,000 | $182,953,000 | $17,447,000 | $25,816,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Product | $451,360,000 | $180,059,000 | $14,729,000 | $0 | — | — |
| License and Collaboration | $0 | $2,894,000 | $2,718,000 | — | — | — |
| Collaboration Revenue | — | — | — | — | $3,960,000 | $0 |
| License Fees and Collaboration | — | — | — | $25,816,000 | — | — |
| License And Service | — | — | — | — | $53,067,000 | $0 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | -$70,969,000 | -$120,569,000 | -$143,158,000 | -$62,712,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | -15.7% | -65.9% | -820.5% | -242.9% |